Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy
dc.contributor.author | Li, Yong Tao | en_US |
dc.contributor.author | Kwon, Young Min | en_US |
dc.contributor.author | Spangrude, Gerald J. | en_US |
dc.contributor.author | Liang, Jun Feng | en_US |
dc.contributor.author | Chung, Hee Sun | en_US |
dc.contributor.author | Park, Yoon Jeong | en_US |
dc.contributor.author | Yang, Victor C. | en_US |
dc.date.accessioned | 2009-09-02T14:39:31Z | |
dc.date.available | 2010-12-01T21:34:38Z | en_US |
dc.date.issued | 2009-10 | en_US |
dc.identifier.citation | Li, Yong Tao; Kwon, Young Min; Spangrude, Gerald J.; Liang, Jun F.; Chung, Hee Sun; Park, Yoon Jeong; Yang, Victor C. (2009). "Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy." Journal of Biomedical Materials Research Part A 91A(1): 209-220. <http://hdl.handle.net/2027.42/63612> | en_US |
dc.identifier.issn | 1549-3296 | en_US |
dc.identifier.issn | 1552-4965 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63612 | |
dc.description.abstract | Asparaginase (ASNase) is an enzyme drug presently approved for the induction of remission in the treatment of patients with acute lymphoblastic leukemia (ALL). The cytotoxic effect of ASNase is derived from its ability to deplete asparagine, an essential amino acid required by certain types of leukemia cells for protein synthesis and survival. Despite its efficacy in enhancing disease remission rate and prolonging complete remission duration in ALL patients, ASNase therapy is nevertheless confounded by a number of serious toxic effects, particularly to organs associated with high protein production (e.g., liver, pancreas), due to the systemic depletion of asparagine. Presented herein is a modified version of our previously established ATTEMPTS protein delivery system that carries the potential to permit a tumor specific, intracellular delivery of ASNase, thereby allowing for a significant reduction of ASNase-induced systemic toxicity. In a previous paper, we already demonstrated the in vitro feasibility of this heparin/protamine-regulated, TAT-mediated system in delivering ASNase directly into ASNase-sensitive murine lymphoma cells. In this article, we further validated the in vivo applicability of this system in animals harboring ASNase-encapsulated L5178Y lymphoma cells. Preliminary results showed that animals inoculated with L5178Y cells containing TAT-ASNase exhibited an extended survival rate of ∼13% over those harboring L5178Y cells without the encapsulation of ASNase. Furthermore, the TAT-ASNase-treated mice also displayed a significantly improved hematological and liver histological status than the control groups. These findings bring promise to the use of the modified ATTEMPTS delivery system in achieving enhanced ASNase therapy. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009 | en_US |
dc.format.extent | 770695 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Chemistry | en_US |
dc.subject.other | Polymer and Materials Science | en_US |
dc.title | Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Biomedical Engineering | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, Tianjin University, Tianjin, People's Republic of China 300072 ; Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065 | en_US |
dc.contributor.affiliationum | Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065 | en_US |
dc.contributor.affiliationum | Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065 | en_US |
dc.contributor.affiliationum | Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, Tianjin University, Tianjin, People's Republic of China 300072 ; Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065 ; Tianjin Key Laboratory for Modern Drug Delivery and High Efficiency, Tianjin University, Tianjin, People's Republic of China 300072 | en_US |
dc.contributor.affiliationother | Department of Hematology, School of Medicine, University of Utah, Salt Lake City, Utah 84112 | en_US |
dc.contributor.affiliationother | Department of Chemical Biology, Stevens Institute of Technology, Hoboken, New Jersey 07030 | en_US |
dc.contributor.affiliationother | College of Dentistry, Seoul National University, Seoul 110-749, Korea | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63612/1/32204_ftp.pdf | |
dc.identifier.doi | 10.1002/jbm.a.32204 | en_US |
dc.identifier.source | Journal of Biomedical Materials Research Part A | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.